Cancer BiologybioRxiv
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer
S. A. Wander, O. Cohen, X. Gong…·N. Wagle
The paper identifies eight resistance mechanisms to CDK4/6 inhibitors in HR+ breast cancer, present in 80% of resistant tumors, with potential therapeutic strategies.
DOI 10.1158/2159-8290.cd-19-1390